Fig. 2: Epigenetic regulators that can serve as therapeutic strategies. | Cell Death Discovery

Fig. 2: Epigenetic regulators that can serve as therapeutic strategies.

From: Comprehensive view on chemotherapy-free management of acute myeloid leukemia by using venetoclax in combination with targeted and/or immune therapies

Fig. 2

A IDH role in DNA methylation. While wild-type (WT) IDH leads to normal DNA methylation and physiological production of alfa-ketoglutarate, mutant forms of IDH can lead to aberrant secretion of 2-hydroxy-glutarate (2-HG) and modified DNA methylation leading to a block in cell differentiation. The use of IDH-inhibitors in IDH mutant cells restores the normal DNA methylation pattern B The possible use of a triplet therapy including venetoclax, hypomethylating agents and IDH-inhibitors. The outcome would be a hypomethylated DNA, normal methylation due to IDH-inhibition and triggered apoptosis.

Back to article page